Associate Editor, Ophthalmology Times
President and CEO of Ashvattha Therapeutics talks about the company's unique nanomedicine technology
January 28th 2024David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.
Read More
OKYO Pharma announces positive results from phase 2 trial of OK-101 in dry eye disease
January 8th 2024According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”
Read More
Viridian Therapeutics chooses VRDN-003 as lead subcutaneous therapy for Thyroid Eye Disease
December 19th 2023Viridian's VRDN-003, a subcutaneous therapy for thyroid eye disease, has demonstrated positive data in a Phase 1 clinical study, with an extended half-life of 40-50 days. The company plans to initiate global pivotal trials in mid-2024, aiming to transform TED treatment with less frequent dosing intervals.
Read More
Curing genetic blindness with space-enhanced artificial retinas
December 13th 2023LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.
Read More
Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals
December 12th 2023Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.
Read More
Grant from the Optica Foundation fuels research to help detect undetectable glaucoma
December 12th 2023The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.
Read More
TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and s being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
Read More